Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.81 |
| ▸ | DRD2 | P14416 | 1/20 | 0.57 |
| ▸ | DRD1 | P21728 | 1/20 | 0.57 |
| ▸ | DRD4 | P21917 | 1/20 | 0.57 |
| ▸ | DRD5 | P21918 | 1/20 | 0.57 |
| ▸ | DRD3 | P35462 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7114790 | 0.95 | HTR6 (0.77) | HTR6DRD2DRD1DRD4DRD5 | |
| SCHEMBL7114786 | 0.95 | HTR6 (0.77) | HTR6DRD2DRD1DRD4DRD5 | |
| SCHEMBL7252843 | 0.94 | HTR6 (0.78) | HTR6DRD2DRD1DRD4DRD5 | |
| SCHEMBL7122467 | 0.91 | HTR6 (0.77) | HTR6 | |
| SCHEMBL7122465 | 0.91 | HTR6 (0.77) | HTR6 | |
| SCHEMBL7116714 | 0.91 | HTR6 (0.83) | HTR6DRD2DRD1DRD4DRD5 | |
| SCHEMBL7113766 | 0.90 | HTR6 (0.79) | HTR6 | |
| SCHEMBL7113769 | 0.90 | HTR6 (0.79) | HTR6 | |
| SCHEMBL7111440 | 0.90 | HTR6 (1.00) | HTR6DRD2DRD1DRD4DRD5 | |
| SCHEMBL7120464 | 0.90 | HTR6 (0.81) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6638972-B2 | Disorders of 5HT-6 receptors | WYETH | 2003-10-28 | — | — | US | claimed |
| US-20030153599-A1 | Chroman and benzofuran derivatives as 5-hydroxytryptamine-6 ligands | WYETH | 2003-08-14 | — | — | US | claimed |
| WO-2003029239-A1 | CHROMAN AND BENZOFURAN DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2003-04-10 | — | — | WO | claimed |
| US-6638972-B2 | Disorders of 5HT-6 receptors | WYETH | 2003-10-28 | — | — | US | disclosed |
| US-20030153599-A1 | Chroman and benzofuran derivatives as 5-hydroxytryptamine-6 ligands | WYETH | 2003-08-14 | — | — | US | disclosed |
| WO-2003029239-A1 | CHROMAN AND BENZOFURAN DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153599-A1 | Chroman and benzofuran derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR1F, HTR1A | HTR6 1/4885DRD2 212/4885DRD1 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.